Japan’s Teijin Pharma Gout Drug TMX-67 Gains EMEA Positive Opinion
This article was originally published in PharmAsia News
Teijin Pharma received a positive opinion from the Europe Medicines Agency for gout drug TMX-67 through its licensee for Europe, Ipsen. An oral, once-daily drug, TMX-67 (febuxostat) is a novel xanthine oxidase inhibitor with a different structure than allopurinol, the only available gout drug developed 40 years ago. Teijin views IMX-67 as a way to expand into overseas markets. It also plans to resubmit an application for approval in Japan. Additional Phase III trials are being conducted in the U.S., and trials are also being conducted in Korea. After obtaining European approval, Ipsen plans to sell the drug under the name Adenuric.(Click for more-Japanese language
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.